Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful completion of an out-licensing project conducted on behalf of its client, Elthera AG of Switzerland. Plexus Ventures served as the exclusive business development advisor to Elthera in the partnering of its first-in-class antibody directed at a target widely expressed on solid tumors. On February 13, 2023, it was announced that LegoChemBio of South Korea acquired the rights to Elthera’s antibody to develop a novel antibody-drug conjugate (ADC) therapy.
Richard Brown, Managing Partner, Plexus Ventures, stated: “The Elthera team has conducted a rigorous development program to demonstrate the potential of this novel antibody. The announced transaction will combines Elthera’s first in-class antibody with an industry-leading ADC technology into a promising new antibody-drug conjugate with high therapeutic potential in different tumor indications. ”
Dr. Anne Schmidt, co-founder and CEO, Elthera AG, commented: “We appreciated the strong support of Plexus Ventures, their deep proficiency in the science and sound business development advice which contributed to this positive outcome.”
Click here to view the press release on Elthera’s webpage.
